Welcome to our dedicated page for IMMNOV news (Ticker: IMMNOV), a resource for investors and traders seeking the latest updates and insights on IMMNOV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMMNOV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMMNOV's position in the market.
Immunovia (IMMNOV: Nasdaq Stockholm) announces that its CLARITI study results have been selected for a distinguished plenary presentation at the Digestive Disease Week® (DDW) 2025 conference on May 5, 2025. The study was chosen as one of only six abstracts for the AGA Institute Council's Pancreatic Disorders Section Distinguished Abstract Plenary.
Dr. Aimee Lee Lucas, Chief of Gastroenterology at Mount Sinai West and Mount Sinai Morningside Hospitals, will present findings on the clinical validation of Immunovia's novel blood-based multi-biomarker test for early pancreatic ductal adenocarcinoma (PDAC) detection in high-risk populations. As a member of Immunovia's Scientific Advisory Board, Dr. Lucas contributed to the study's design and sample collection.
Immunovia (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, announced it is searching for a new Chief Financial Officer as it prepares to commercialize its test in the USA in the second half of 2025. The company seeks a CFO with diagnostics or med tech operating experience, US industry contacts, and expertise in communicating with global capital markets.
Current CFO Karin Almqvist Liwendahl will step down at the end of Q1 2025, after contributing to streamlining the organization, lowering operating costs, and reducing cash burn over the past three years. In the interim, CEO Jeff Borcherding and the finance team will assume financial leadership responsibilities.
Immunovia focuses on developing blood-based testing for early pancreatic cancer detection. The company estimates that 1.8 million high-risk individuals in the USA could benefit from annual surveillance testing, making it the world's largest market for pancreatic cancer detection.
Immunovia AB (IMMNOV: Nasdaq Stockholm) has announced its Nomination Committee appointments ahead of the 2025 Annual General Meeting. The committee comprises four members representing 5.65% of shares and votes: Christer Køhler (representing Jens Henrik Jensen), Mats Leifland (representing Vincent Saldell), Sara Ek (representing Carl Borrebaeck), and Peter Høngaard Andersen as Board Chair.
CEO Jeff Borcherding declined to appoint a representative to ensure committee independence. The committee will prepare proposals for the AGM scheduled for May 14, 2025, including board nominations and compensation recommendations. The focus is on ensuring board competencies align with the company's transition from R&D to US commercialization.
Immunovia focuses on developing blood-based testing for early pancreatic cancer detection, targeting the US market where an estimated 1.8 million high-risk individuals could benefit from annual surveillance testing.
Immunovia (IMMNOV) announced the publication of its discovery study in the Journal of Proteome Research, marking it as the largest pancreatic cancer proteomics study to date. The study identified 41 protein biomarkers that strongly correlate with pancreatic ductal adenocarcinoma (PDAC). The research evaluated approximately 3,000 proteins in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients.
Five of these biomarkers were selected for Immunovia's next-generation test, which demonstrated excellent sensitivity and specificity in detecting early-stage pancreatic cancer. The company plans to launch this test for high-risk individuals in the second half of 2025.
Immunovia reported significant achievements in 2024 and outlined plans for 2025. The company successfully developed and validated its next-generation pancreatic cancer detection test, achieving 94% specificity and 78% sensitivity in a large clinical validation study of 1,066 blood samples. The test outperformed CA19-9 biomarker by 14 percentage points and showed even better results (83% sensitivity, 96% specificity) in more recent samples.
For 2025, Immunovia plans to launch the test in the US during the second half of the year, targeting medical centers with high-risk pancreatic cancer surveillance programs. The company is seeking strategic partnerships with large diagnostics companies to accelerate commercialization and will conduct additional clinical studies to secure reimbursement.
Immunovia (IMMNOV) announced that CEO Jeff Borcherding and board members will fully exercise their TO2 warrants from the May 2024 rights issue. In total, holders of 1,651,608 warrants have confirmed their intention to exercise during the upcoming period. Each TO2 warrant allows subscription for one new share at 70% of the volume-weighted average price during December 12-27, 2024, with a cap at 125% of the rights issue price (SEK 0.63). The subscription period runs from January 2-16, 2025.
The CEO expressed confidence in the company's mission and recent CLARITI study results validating their next-generation pancreatic cancer detection test. Immunovia focuses on early detection of pancreatic cancer through blood-based testing, targeting the US market where an estimated 1.8 million high-risk individuals could benefit from annual surveillance.
Immunovia (IMMNOV), a pancreatic cancer diagnostics company, announced a webcast scheduled for December 17, 2024, at 3 pm CET to discuss the positive clinical validation results of their next-generation pancreatic cancer test, which were published on December 9, 2024.
The webcast will feature presentations from key company executives including CEO Jeff Borcherding, VP Clinical and Medical Affairs Dr. Norma Alonzo Palma, and Laboratory Director Dr. Lisa Ford. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai, will provide additional perspective on the study outcomes.
The company focuses on developing blood-based testing for early pancreatic cancer detection, targeting the US market where an estimated 1.8 million individuals are at high risk and could benefit from annual surveillance testing.
Immunovia (NASDAQ Stockholm: IMMNOV) will present results from its recently completed model-development study of their next-generation pancreatic cancer detection test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC). The company's abstract was accepted and recognized for inclusion in the Henry Lynch Lecture. Immunovia is currently conducting a clinical validation study of its next-generation test, expected to complete in December 2024, with plans to launch the test in 2025. The company estimates that in the USA, 1.8 million individuals at high-risk for pancreatic cancer could benefit from annual surveillance testing.
Immunovia will present updates on its next-generation pancreatic cancer detection test at the annual PRECEDE Consortium meeting. The test showed 85% sensitivity and 98% specificity in a model-development study of 623 patient samples. The PRECEDE Consortium, comprising 51 pancreatic centers worldwide, aims to increase five-year survival rates to 50% through early detection research. The consortium has enrolled over 7,000 of its targeted 10,000 high-risk patients. Immunovia plans to complete clinical validation in December 2024 and launch the test in 2025.
Immunovia (IMMNOV: Nasdaq Stockholm) has successfully acquired all blood samples needed to clinically validate its next-generation test for pancreatic cancer. The company has secured over 1,000 blood samples, including 200+ from early-stage pancreatic cancer patients and 800+ from high-risk individuals without cancer. This marks a key milestone towards completing one of the largest clinical validation studies of a pancreatic cancer biomarker test to date.
The study aims to confirm the sensitivity and specificity of Immunovia's new test in differentiating early-stage pancreatic cancer samples from those without cancer. Collaborators include researchers from the University of Pittsburgh, Oregon Health and Science University, University of Verona, and the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Immunovia expects to complete the study in December 2024 and launch the test later in 2025.
